Purpose We investigated the consistent efficacy and safety of eflapegrastim, a novel long-acting granulocyte-colony stimulating factor (G-CSF), in Koreans and Asians compared with the pooled population of two global phase 3 trials.
Materials and Methods Two phase 3 trials (ADVANCE and RECOVER) evaluated the efficacy and safety of fixed-dose eflapegrastim (13.2 mg/0.6 mL [3.6 mg G-CSF equivalent]) compared to pegfilgrastim (6 mg based on G-CSF) in breast cancer patients who received neoadjuvant or adjuvant docetaxel/cyclophosphamide. The primary objective was to demonstrate non-inferiority of eflapegrastim compared to pegfilgrastim in mean duration of severe neutropenia (DSN) in cycle 1, in Korean and Asian subpopulations.
Results Among a total of 643 patients randomized to eflapegrastim (n=314) or pegfilgrastim (n=329), 54 Asians (29 to eflapegrastim and 25 to pegfilgrastim) including 28 Koreans (14 to both eflapegrastim and pegfilgrastim) were enrolled. The primary endpoint, DSN in cycle 1 in the eflapegrastim arm was non-inferior to the pegfilgrastim arm in Koreans and Asians. The DSN difference between the eflapegrastim and pegfilgrastim arms was consistent across populations: –0.120 days (95% confidence interval [CI], –0.227 to –0.016), –0.288 (95% CI, –0.714 to 0.143), and –0.267 (95% CI, –0.697 to 0.110) for pooled population, Koreans and Asians, respectively. There were few treatment-related adverse events that caused discontinuation of eflapegrastim (1.9%) or pegfilgrastim (1.5%) in total and no notable trends or differences across patient populations.
Conclusion This study may suggest that eflapegrastim showed non-inferior efficacy and similar safety compared to pegfilgrastim in Koreans and Asians, consistently with those of pooled population.
Citations
Citations to this article as recorded by
Comparison of Prophylactic Efficacy of Eflapegrastim and Pegteograstim for Chemotherapy-induced Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX/mFOLFIRINOX Eui Seon Lee, Min Jung Geum, Jong Hee Ko, Jae Song Kim, Eun Sun Son, Yun Mi Yu Journal of Korean Society of Health-System Pharmacists.2024; 41(3): 253. CrossRef
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
Cancer Res Treat. 2018;50(3):835-842. Published online August 29, 2017
Purpose
Poziotinib, a pan-human epidermal growth factor receptor 2 (HER) tyrosine kinase inhibitor, has shown potent activity againstwild type of epidermal growth factorreceptor(EGFR) family kinases including EGFR, HER2, and HER4 and EGFR-mutant cells in vitro. Two phase I studies were conducted to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, and antitumor activity against advanced solid tumors.
Materials and Methods
Standard 3+3 dose escalation scheme using two different dosing schedules were studied: once daily, 14-day on, and 7-day off (intermittent schedule); and once daily continuous dosing with food effect. Additional patients were enrolled in an expansion cohort.
Results
A total of 75 patients were enrolled in the two studies. The most common drug-related treatment-emergent adverse eventswere diarrhea,rash, stomatitis, pruritus, and anorexia. Doselimiting toxicities were grade 3 diarrhea in the intermittent schedule and grade 3 anorexia and diarrhea in the continuous dosing schedule. The MTDs were determined as 24 mg/day in the intermittent dosing schedule and 18 mg/day in the continuous dosing schedule. Eight (16%) and 24 (47%) of 51 evaluable patients in the intermittent schedule achieved partial response (PR) and stable disease (SD), respectively. Four (21%) and six (32%) of 19 evaluable patients in continuous dosing schedule achieved PR and SD, respectively. Patients with PR (n=7) or SD ≥ 12 weeks (n=7) had HER2 amplification (n=7; breast cancer, 5; and stomach cancer, 2) and EGFR amplification (n=1, squamous cell lung cancer).
Conclusion
Poziotinib was safe and well tolerated in patients with advanced solid tumors. It showed an encouraging activity against EGFR-mutant and HER2-amplified cancers.
Citations
Citations to this article as recorded by
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, Adrian Sacher, Paul Wheatley-Price, Stephanie Snow, Ming-Sound Tsao, Natasha B. Leighl, Ilidio Martins, Parneet Cheema, Geoffrey Liu, Quincy S. C. Chu Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, Masato Chiba, Masaki Shimoji, Masaoki Ito, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani, Tetsuya Mitsudomi Journal of Thoracic Oncology.2024; 19(1): 71. CrossRef
Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens Azadeh Nasrazadani, Juan Luis Gomez Marti, Kate Lathrop, Alvaro Restrepo, Szu-Yun Leu, Gajanan Bhat, Adam Brufsky Breast Cancer Research and Treatment.2024; 205(1): 29. CrossRef
HER2-targeted therapies beyond breast cancer — an update Jeesun Yoon, Do-Youn Oh Nature Reviews Clinical Oncology.2024; 21(9): 675. CrossRef
Emerging Targeted Therapies for HER2-Positive Breast Cancer María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci Cancers.2023; 15(7): 1987. CrossRef
Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS Shuanghu Wang, Mengming Xia, Yu Wang, Zebei Lu, Peiwu Geng, Dapeng Dai, Yunfang Zhou, Qingjun Wu Thoracic Cancer.2023; 14(14): 1276. CrossRef
Neratinib for HER2-positive breast cancer with an overlooked option Liting Guo, Weiwei Shao, Chenfei Zhou, Hui Yang, Liu Yang, Qu Cai, Junqing Wang, Yan Shi, Lei Huang, Jun Zhang Molecular Medicine.2023;[Epub] CrossRef
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Kenichi Suda, Kazuko Sakai, Hidenori Sato, Tetsuya Mitsudomi JTO Clinical and Research Reports.2023; 4(9): 100554. CrossRef
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer Arnaldo Marín, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker Cancer Research.2023; 83(18): 3145. CrossRef
In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes Salman Alamery, Anfal AlAjmi, Tanveer A. Wani, Seema Zargar Medicina.2023; 59(11): 1923. CrossRef
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, Maximino Redondo, Teresa Téllez Cancers.2023; 15(23): 5499. CrossRef
Novel HER-2 Targeted Therapies in Breast Cancer Catarina Lopes Fernandes, Diogo J. Silva, Alexandra Mesquita Cancers.2023; 16(1): 87. CrossRef
Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer Jiyun Lee, Yeon Hee Park Future Oncology.2022; 18(1): 7. CrossRef
Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V. Heymach, Mark A. Socinski Journal of Clinical Oncology.2022; 40(7): 710. CrossRef
HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies Xin Yu, Xianxiu Ji, Chunxia Su Frontiers in Oncology.2022;[Epub] CrossRef
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan Cancer Cell.2022; 40(7): 754. CrossRef
Tailoring antiHer2 treatment strategies in breast cancer and beyond Palma Fedele, Valeria Sanna, Anna Natalizia Santoro, Maria Laura Iaia, Alessandro Fancellu Current Problems in Cancer.2022; 46(5): 100892. CrossRef
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao Biomarker Research.2022;[Epub] CrossRef
Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman Journal of Personalized Medicine.2022; 12(10): 1651. CrossRef
An ultra-performance LC–MS/MS method for determination of JRF103 in human plasma: application in first in-patient study Ying Jin, Xiangjie Di, Lisha Fu, Mengyu Zhang, Neng Qiu, Runhan Liu, Fangqun Li, Xiaohui Qi, Xiaoxu Wang, Yongsheng Wang, Zhenlei Wang Bioanalysis.2022; 14(17): 1165. CrossRef
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino Critical Reviews in Oncology/Hematology.2021; 160: 103299. CrossRef
Effects of dacomitinib on the pharmacokinetics of poziotinib
in vivo
and
in vitro
Weiping Ji, Jiquan Shen, Bo Wang, Feifei Chen, Deru Meng, Shuanghu Wang, Dapeng Dai, Yunfang Zhou, Changxiong Wang, Quan Zhou Pharmaceutical Biology.2021; 59(1): 455. CrossRef
Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib Lara Ulrich, Alicia FC Okines Breast Cancer: Targets and Therapy.2021; Volume 13: 361. CrossRef
Current therapeutic options for gastric adenocarcinoma C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer Barbara Melosky, Paul Wheatley-Price, Rosalyn A. Juergens, Adrian Sacher, Natasha B. Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B. Card, Quincy Chu Lung Cancer.2021; 160: 136. CrossRef
Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer Chia-Jung Li, Yen-Dun Tony Tzeng, Yi-Han Chiu, Hung-Yu Lin, Ming-Feng Hou, Pei-Yi Chu Cancers.2021; 13(12): 2978. CrossRef
Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview Debasis Das, Jingbing Wang, Jian Hong ChemMedChem.2021; 16(16): 2459. CrossRef
Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors Seyed-Omar Zaraei, Rawan M. Sbenati, Nour N. Alach, Hanan S. Anbar, Randa El-Gamal, Hamadeh Tarazi, Mahmoud K. Shehata, Mohammed S. Abdel-Maksoud, Chang-Hyun Oh, Mohammed I. El-Gamal European Journal of Medicinal Chemistry.2021; 224: 113674. CrossRef
Breast Cancer Treatments: Updates and New Challenges Anna Burguin, Caroline Diorio, Francine Durocher Journal of Personalized Medicine.2021; 11(8): 808. CrossRef
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations M. Riudavets, I. Sullivan, P. Abdayem, D. Planchard ESMO Open.2021; 6(5): 100260. CrossRef
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim Cancer Medicine.2021; 10(20): 7012. CrossRef
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial Akira Hamada, Kenichi Suda, Takamasa Koga, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuro Uchida, Tetsuya Mitsudomi Lung Cancer.2021; 162: 79. CrossRef
HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy Ioannis A. Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N. Syrigos Pharmaceuticals.2021; 14(12): 1300. CrossRef
Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang Journal of Thoracic Oncology.2020; 15(6): 962. CrossRef
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu Pharmacology & Therapeutics.2020; 206: 107438. CrossRef
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard Critical Reviews in Oncology/Hematology.2020; 148: 102906. CrossRef
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang, Xiaoyan Ma, Minghui Wang, Wenjing Wang, Songhui Zhao, Kai Wang, Song Gao, Li Zhang The Oncologist.2020; 25(3): e545. CrossRef
Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study Teresa Moran, Alvaro Taus, Edurne Arriola, Carlos Aguado, Manuel Dómine, Ana Gómez Rueda, Antonio Calles, Susana Cedrés, Nuria Viñolas, Dolores Isla, Ramón Palmero, María Sereno, Victor Diaz, Oscar Juan, Raquel Marsé, Paloma Martín Martorell, José Miguel Clinical Lung Cancer.2020; 21(5): 428. CrossRef
HER2-positive advanced breast cancer treatment in 2020 Marcelle G. Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja Cancer Treatment Reviews.2020; 88: 102033. CrossRef
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices? Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, Anthony Gonçalves Cancers.2020; 12(6): 1573. CrossRef
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang, Shucai Zhang Frontiers in Oncology.2020;[Epub] CrossRef
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park Breast Cancer Research and Treatment.2020; 184(3): 743. CrossRef
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins Jordi Remon, Lizza E.L. Hendriks, Andres F. Cardona, Benjamin Besse Cancer Treatment Reviews.2020; 90: 102105. CrossRef
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni Critical Reviews in Oncology/Hematology.2020; 156: 103119. CrossRef
Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer Xue Yang, Dapeng Wu, Shengli Yuan Technology in Cancer Research & Treatment.2020;[Epub] CrossRef
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang Cancers.2020; 12(11): 3249. CrossRef
Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo Gastrointestinal Disorders.2020; 3(1): 1. CrossRef
Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use Apurva Pandey, Adam M. Brufsky Clinical Breast Cancer.2019; 19(1): e7. CrossRef
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry Debasis Das, Jian Hong European Journal of Medicinal Chemistry.2019; 170: 55. CrossRef
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer Wei Jiang, Meiju Ji Seminars in Cancer Biology.2019; 59: 3. CrossRef
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer Tae-Yong Kim, Hye Sook Han, Keun-Wook Lee, Dae Young Zang, Sun Young Rha, Young Iee Park, Jin-Soo Kim, Kyung-Hun Lee, Se Hoon Park, Eun-Kee Song, Soo-A Jung, NaMi Lee, Yeul Hong Kim, Jae Yong Cho, Yung-Jue Bang Gastric Cancer.2019; 22(6): 1206. CrossRef
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown Cancers.2019; 11(6): 737. CrossRef
Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positi Ji‐Yeon Kim, Eunjin Lee, Kyunghee Park, Hae Hyun Jung, Woong‐Yang Park, Kyung‐Hun Lee, Joohyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee Hyun Kim, Ki Hyeong Lee, Seock‐Ah Im, Yeon Hee Park International Journal of Cancer.2019; 145(6): 1669. CrossRef
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha The Oncologist.2019; 24(12): e1303. CrossRef
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Makoto Suzuki, Pasi A. Jänne, Tetsuya Mitsudomi Lung Cancer.2018; 126: 72. CrossRef
A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial Yeon Hee Park, Kyung‐Hun Lee, Joo Hyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee‐Hyun Kim, Ki Hyeong Lee, Jin Seok Ahn, Tae‐Yong Kim, Gun Min Kim, In Hae Park, Sung‐Bae Kim, Se Hyun Kim, Hye Sook Han, Young‐Hyuck Im, Jin‐Hee Ahn, Jung‐Yong Kim, Jahoon Kang International Journal of Cancer.2018; 143(12): 3240. CrossRef
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa Clinical Cancer Research.2018; 24(24): 6548. CrossRef
Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung Ho Nam, Hyesun Han, Jina Jung, Jin Soo Lee
Cancer Res Treat. 2017;49(1):10-19. Published online May 3, 2016
Purpose We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs.
Materials and Methods This single-arm phase II study included EGFR-mutant lung adenocarcinoma with AR to erlotinib or gefitinib based on the Jackman criteria. Patients received poziotinib 16 mg orally once daily in a 28-day cycle. The primary endpoint was progression-free survival (PFS). Prestudy tumor biopsies and blood samples were obtained to determine resistance mechanisms.
Results Thirty-nine patients were treated. Tumor genotyping was determined in 37 patients; 19 EGFR T790M mutations and two PIK3CAmutations were detected in the prestudy tumors, and seven T790M mutations were detected in the plasma assay. Three (8%; 95% confidence interval [CI], 2 to 21) and 17 (44%; 95% CI, 28 to 60) patients had partial response and stable disease, respectively. The median PFS and overall survival were 2.7 months (95% CI, 1.8 to 3.7) and 15.0 months (95% CI, 9.5 to not estimable), respectively. A longer PFS was observed for patients without T790M or PIK3CA mutations in tumor or plasma compared to those with these mutations (5.5 months vs. 1.8 months, p=0.003). The most frequent grade 3 adverse events were rash (59%), mucosal inflammation (26%), and stomatitis (18%). Most patients required one (n=15) or two (n=15) dose reductions.
Conclusion Low activity of poziotinib was detected in patients with EGFR-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.
Citations
Citations to this article as recorded by
Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions Yangyang Wang, Yongyuan Zhang, Nana Ren, Fangting Li, Lin Lu, Xin Zhao, Zhigang Zhou, Mengyu Gao, Meng Wang Frontiers in Oncology.2024;[Epub] CrossRef
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante Journal of Personalized Medicine.2024; 14(7): 752. CrossRef
3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation Yoo-mi Choi, Haram Lee, Minjun Ann, Minyeong Song, Jinguen Rheey, Jinah Jang Biofabrication.2023; 15(3): 034104. CrossRef
Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao Frontiers in Oncology.2022;[Epub] CrossRef
Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial Juan Li, Yuke Tian, Min Zheng, Jun Ge, Jiliang Zhang, Dejun Kong, Mei Chen, Ping Yu Thoracic Cancer.2022; 13(24): 3496. CrossRef
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar Biomolecules.2021; 11(2): 160. CrossRef
Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response Devin G. Roller, Stephen A. Hoang, Kristopher D. Rawls, Katherine A. Owen, Michael B. Simmers, Robert A. Figler, Julia D. Wulfkuhle, Emanuel F. Petricoin, Brian R. Wamhoff, Daniel Gioeli Scientific Reports.2021;[Epub] CrossRef
Geriatric Nutritional Risk Index as a Prognostic Factor for Mortality in Elderly Patients with Moderate to Severe Traumatic Brain Injuries Wei-Ti Su, Ching-Hua Tsai, Chun-Ying Huang, Sheng-En Chou, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh Risk Management and Healthcare Policy.2021; Volume 14: 2465. CrossRef
Geriatric nutritional risk index in screening malnutrition among young adult and elderly trauma patients Yueh-Wei Liu, Ching-Hua Tsai, Sheng-En Chou, Wei-Ti Su, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh Formosan Journal of Surgery.2021; 54(5): 183. CrossRef
In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation Yinli Gao, Hanxun Wang, Jian Wang, Maosheng Cheng Journal of Biomolecular Structure and Dynamics.2020; 38(14): 4119. CrossRef
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard Critical Reviews in Oncology/Hematology.2020; 148: 102906. CrossRef
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy Afshin Derakhshani, Zohreh Rezaei, Hossein Safarpour, Morteza Sabri, Atefeh Mir, Mohammad Amin Sanati, Fatemeh Vahidian, Ali Gholamiyan Moghadam, Ali Aghadoukht, Khalil Hajiasgharzadeh, Behzad Baradaran Journal of Cellular Physiology.2020; 235(4): 3142. CrossRef
Toward a More Precise Future for Oncology Yonina R. Murciano-Goroff, Barry S. Taylor, David M. Hyman, Alison M. Schram Cancer Cell.2020; 37(4): 431. CrossRef
Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer Jigar D. Vanza, Rashmin B. Patel, Mrunali R. Patel Journal of Drug Delivery Science and Technology.2020; 60: 102070. CrossRef
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang Cancers.2020; 12(11): 3249. CrossRef
Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib Nishan Tchekmedyian, Bill Paxton, Francois Lebel, Lena Keossayan, John V. Heymach JTO Clinical and Research Reports.2020; 1(4): 100081. CrossRef
Geriatric Nutritional Risk Index as a Screening Tool to Identify Patients with Malnutrition at a High Risk of In-Hospital Mortality among Elderly Patients with Femoral Fractures—A Retrospective Study in a Level I Trauma Center Wei-Ti Su, Shao-Chun Wu, Chun-Ying Huang, Sheng-En Chou, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh International Journal of Environmental Research and Public Health.2020; 17(23): 8920. CrossRef
Geriatric Nutritional Risk Index as a Tool to Evaluate Impact of Malnutrition Risk on Mortality in Adult Patients with Polytrauma Cheng-Hsi Yeh, Shao-Chun Wu, Sheng-En Chou, Wei-Ti Su, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh International Journal of Environmental Research and Public Health.2020; 17(24): 9233. CrossRef
Association between Geriatric Nutritional Risk Index and Mortality in Older Trauma Patients in the Intensive Care Unit Hang-Tsung Liu, Shao-Chun Wu, Ching-Hua Tsai, Chi Li, Sheng-En Chou, Wei-Ti Su, Shiun-Yuan Hsu, Ching-Hua Hsieh Nutrients.2020; 12(12): 3861. CrossRef
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology Rashmi R. Shah, Devron R. Shah Drug Safety.2019; 42(2): 181. CrossRef
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer Wei Jiang, Meiju Ji Seminars in Cancer Biology.2019; 59: 3. CrossRef
Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer Juliane Martin, Annika Lehmann, Frederick Klauschen, Michael Hummel, Dido Lenze, Christian Grohé, Antje Tessmer, Joachim Gottschalk, Berndt Schmidt, Hans-Wilhelm Pau, Christian Witt, Stefan Moegling, Robert Kromminga, Korinna Jöhrens Clinical Lung Cancer.2019; 20(5): 350. CrossRef
Metastasiertes Lungenkarzinom – therapierbare molekulare Alterationen W. M. Brückl, J. H. Ficker Der Pneumologe.2019; 16(6): 343. CrossRef
Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib Juyin Yang, Jian Yang, Shao Ban, Xinmin Li, Xingde Chen, Jihua Yang, Jun Qian Journal of Thoracic Oncology.2019; 14(9): e198. CrossRef
Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective Shui-Ming Bao, Qing-Hui Hu, Wen-Ting Yang, Yao Wang, Yin-Ping Tong, Wen-Dai Bao Anti-Cancer Agents in Medicinal Chemistry.2019; 19(8): 984. CrossRef
Maximum allele frequency observed in plasma: A potential indicator of liquid biopsy sensitivity Yong Tang, Xianling Liu, Zhu'an Ou, Zhe He, Qihang Zhu, Ye Wang, Mei Yang, Junyi Ye, Han Han‑Zhang, Guibin Qiao Oncology Letters.2019;[Epub] CrossRef
TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita, Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, D Molecular Cancer Research.2019; 17(11): 2233. CrossRef
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou Cancer Science.2018; 109(4): 1207. CrossRef
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer Jacqulyne P. Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R. Nature Medicine.2018; 24(5): 638. CrossRef
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi Clinical Lung Cancer.2018; 19(5): e775. CrossRef
Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors Yanmei Peng, Qiang Li, Jingyi Zhang, Wen Shen, Xu Zhang, Chenyao Sun, Huijuan Cui BioScience Trends.2018; 12(6): 537. CrossRef
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa Clinical Cancer Research.2018; 24(24): 6548. CrossRef
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs Zhiyong Liang, Ying Cheng, Yuan Chen, Yanping Hu, Wei-Ping Liu, You Lu, Jie Wang, Ye Wang, Gang Wu, Jian-Ming Ying, He-Long Zhang, Xu-Chao Zhang, Yi-Long Wu Cancer Letters.2017; 403: 186. CrossRef
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer Xuefei Li, Caicun Zhou Oncotarget.2017; 8(59): 100801. CrossRef